Stock Groups

Pfizer/BioNTech expect data on shot’s protection against new COVID-19 variant soon -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – Empty vials containing the Pfizer BioNTech COVID-19 “Comirnaty,” vaccine can be seen in a package from a Madrid coronavirus (COVID-19), vaccination center, on November 24, 2021. REUTERS/Sergio Perez/File Photo

By Ludwig Burger

FRANKFURT, Reuters – BioNTechSE (NASDAQ:) stated on Friday that it expected more data about a new worrying coronavirus variant in South Africa within the next two weeks. This will help to determine if its vaccine was produced with a partner. Pfizer Inc (NYSE: ) needs to be revised.

Pfizer said BioNTech and Pfizer expect that they will be able, if needed, to ship the new vaccine in around 100 days.

When BioNTech was asked for comment, it stated that “We are sensitive to the concerns of experts” and had begun investigations into variant B.1.1.529.

We expect to receive more information from laboratory tests within the next two weeks. It said that these data would provide additional information on whether B.1.1.529 might be an escape variant and may need to adjust our vaccine in the event of global spread.”

Evaluate variants are vaccines that bypass the immune system. BioNTech said that Pfizer and BioNTech could redesign their shots in just six weeks. They would also be able ship the initial batches in 100 days.

BioNTech ADRs rose 14.2% to close Friday at $348, while Pfizer shares rose 6.1% to close Friday at $54.

On Friday, global authorities were alarmist at the discovery of the variant. The EU and Britain tightened their border controls in an effort to discover if this mutation is resistant to vaccines.

Pfizer and BioNTech already have developed versions of their mRNA vaccine, based upon the original virus from China. These are designed to attack the so-called Alpha or Delta variants. There are clinical trials underway.

These efforts do not aim to produce commercial products. They are intended to create a routine that regulators can use to speed up future vaccine relaunches.

Evercore ISI’s analysts stated that the data from Qatar for a new variant of the vaccine showed an extremely high degree of efficacy at first, which faded rapidly four months later.

Johnson and Johnson indicated that it was also keeping an eye on emerging COVID-19 strains and is currently testing its effectiveness against these new varieties.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]